COVID-19 Resources
COVID-19 Resources

To continue supporting our physicians and nurses who are on the front lines of managing the influx of critically ill patients, many of whom will develop acute kidney injury (AKI) or experience renal failure during this pandemic, we have consolidated support resources to help you with providing these patients Continuous Renal Replacement Therapy (CRRT). We will be updating this page with additional support materials as they become available so please check back regularly.

New data on Role of Blood Purification with Oxiris in Managing COVID-19 Patients

As COVID-19 continues taking an immense worldwide toll, Baxter is partnering with healthcare providers to advance understanding of the pandemic’s unique treatment challenges. Extracorporeal blood purification (EBP) techniques have played a role in managing critically ill COVID-19 patients; and now the journal Critical Care has published the largest study of its kind on registry data from COVID-19 patients treated with EBP using Baxter’s Oxiris filter set. The study was supported by Baxter through an investigator-initiated research grant. Among the key takeaways, the data showed a reduction in serum IL-6 (a pro-inflammatory cytokine), improvement in indicators of organ dysfunction and a reduction in intensive care unit (ICU) mortality compared to a historical control1. The results provide a strong foundation for future research on this difficult-to-study clinical area.

See more information >

The Role of CRRT and Blood Purification in Managing Patients with COVID-19

Now, more than ever, Continuous Renal Replacement Therapy is a critical therapy to be used for patients with AKI requiring renal replacement therapy and especially for those patients who are hemodynamically unstable. It has been reported in various countries that a subset of patients with COVID-19 will become severely ill, with a sepsis like syndrome and multiorgan failure, including acute kidney injury. In these critical cases, CRRT may be a life sustaining and life saving therapy.

- Mary Gellens, MD

Senior Medical Director
Baxter Healthcare Corporation

The current treatment of COVID-19 with AKI includes general and supportive management and kidney replacement therapy. There is no effective antiviral therapy available at present.

- The Novel Coronavirus 2019 epidemic and kidneys.

Naiker, et al. Kidney Int. 2020 May;97(5):824-828

“As a critical care community, our understanding of how to manage severely ill patients with COVID-19 continues to evolve as we learn more about the virus. Baxter is proud to support new research on the use of extracorporeal blood purification in COVID-19 patients and remains committed to advancing scientific discourse in support of the healthcare providers in the ICU who so selflessly care for these vulnerable patients."

-Reaz Rasul

General manager of our Acute Therapies business Baxter International Inc.

“In our study population, all patients showed significant IL-6 reduction and associated improvement in multiorgan dysfunction, particularly for short-term outcomes such as hemodynamic stability and oxygenation index,”

“These findings provide a strong foundation for further research on EBP in COVID-19 patients and may have a long-term impact on best practices in caring for these patients.”

- Gianluca Villa, M.D., assistant professor of anesthesiology, intensive care and pain medicine

- University of Florence, Italy

COVID-19 and the Critically Ill Patient

COVID-19 manifests primarily as an acute respiratory illness with interstitial and alveolar pneumonia, but it can affect multiple organs such as the kidney2

Early reports suggested a lower incidence (3%–9%) of acute kidney injury (AKI) in patients with COVID-19 compared to SARS and MERS-CoV infections. More recent reports have shown a higher frequency of abnormal kidney function in hospitalized patients, with a 15% prevalence of elevated serum creatinine3

Critically ill patients with COVID-19 infection may present a higher incidence of AKI compared with less sick patients4

Whether AKI associated with COVID-19 is caused by a coronavirus-induced cytopathic effect, a cytokine storm induced systemic inflammatory response, or both remains unclear5

The development of AKI in patients with COVID-19 infection has been associated with an increased risk of in-hospital mortality6

 
Webinars

Webinars

If you want to learn more, join our live webinars

Join our live webinars
 

Confronting Coronavirus: Managing Severe Cases of COVID-19

Jean-Louis Vincent, M.D., Ph.D., a world-renowned critical care specialist at the Erasme Hospital, shares his insights with fellow intensivists on managing severe cases of COVID-19.

Learn more
Image of Dr. Vincent talking about COVID 19

Baxter Education Resources

Baxter offers education in a variety of formats catering to the specific education preferences and needs at your hospital

  • Local Baxter Clinical Representatives
  • Live and On-Demand Webinars
  • Baxter Online Educational Port
Baxter Online Educational Portal Login
Baxter Education Resources

Stay Up-to-Date on the Latest News

Select a logo below to visit their website for more information.

CDC

NephJC

Society of Critical Care Medicine

American Association of Critical-Care Nurses

ASN

CRRT Online

Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19:

a pilot study >

 

References

1. Villa G, et al. Crit Care. 2020; 24:605. 2. Wang D, et al. JAMA. 2020;323(11):1061-1069. 3. Naicker S, et al. Kidney Int. 2020;. doi:10.1016/j.kint.2020.03.001. 4. Arentz M, et al. JAMA. 2020;e204326. doi:10.1001/jama.2020.4326. 5. Pan XW, et al. Intensive Care Med. 2020;1–3. doi:10.1007/s00134-020-06026-1. 6. Cheng Y, et al. Kidney Int. 2020;S0085-2538(20)30255-6. doi:10.1016/j.kint.2020.03.005.

 
 
up button